
Volume Fueling Rise in Part D Specialty Derm Drug Spending
Harvard Medical School researchers reported that from 2013 to 2022, prices were higher and rose faster for specialty medications, but that 80% of the increase in spending 'was due to increased prescriptions, not prices.'
Price increases only accounted for 20% of the total growth in Medicare Part D dermatologic drug spending during the study period, lead author Edward L. Kong, PhD, told Medscape Medical News .
Specialty medications — primarily immunomodulators — 'are just very expensive in general,' and are being rapidly adopted by clinicians, which is driving increased spending, said Kong, who is pursuing an MD degree at the Harvard-MIT Health Sciences and Technology program.
Kong and Arash Mostaghimi, MD, MPA, MPH, medical director of the dermatology consult service at Brigham and Women's Hospital, and associate professor, Harvard Medical School, both in Boston, published their findings in JAMA Dermatology on July 16.
They examined some 95 million prescriptions for Medicare beneficiaries, written by almost 25,000 dermatologists and dermatology-focused advanced practice clinicians. Inflation-adjusted spending increased an average of 16% a year, reaching $2.95 billion in 2022. Over the study time period, specialty drug spending increased just under 30% a year, reaching $2.4 billion in 2022. Spending on nonspecialty medications only grew 0.7% annually during the study period.
By 2022, specialty medications accounted for 81% of all dermatology drug spending, having risen from a third of spending in 2013. Even so specialty medications only represented about 3% of all Medicare Part D dermatology prescriptions in 2022.
Four of the specialty drugs were introduced before 2013: adalimumab (Humira), etanercept (Enbrel), ustekinumab (Stelara), and vismodegib (Erivedge). Six came on the market after 2013: apremilast (Otezla), secukinumab (Cosentyx), ixekizumab (Taltz), dupilumab (Dupixent), guselkumab (Tremfya), risankizumab-rzaa (Skyrizi), and sonidegib (Odomzo).
The older medications had higher price growth than the six newer therapies during the study period. Humira, at the high end, had a 12% price increase per year, while Skyrizi, at the low end, had a 5% yearly decrease.
It's possible that biosimilars for Humira and Stelara — introduced in 2023 and this year — might help restrain cost growth, wrote Kong and Mostaghimi. The introduction of generic oral JAK inhibitors such as tofacitinib may also put a dent in spending, they noted.
Medicare will also likely achieve cost savings in 2026 on Enbrel and Stelara, which are included as part of a law — the Inflation Reduction Act— that gave the health program the power to negotiate prices of certain medications. Patients for affordable drugs now estimate that list prices for Enbrel will drop from around $7000 to $2355 and for Stelara from $13,836 to $4695.
The study did not examine the value of the high-cost specialty drugs, but the rise in prescriptions — indicated by each of the 10 achieving a 1% market share — shows that the medications are being embraced, wrote Kong and Mostaghimi.
The authors' work is similar to other studies that have documented major increases in Medicare Part D dermatologic drug spending being driven in part by increased adoption of specialty medications. A 2022 study in the Journal of the American Academy of Dermatology found that from 2013 to 2019, the price of six dermatology drugs in the top 10 most-prescribed medications decreased, mostly among nonspecialty medications. But in 2013, Enbrel was the most expensive medication in the top 50 most prescribed. Enbrel had been replaced in 2019 by Humira.
In 2020, researchers reported in the Journal of Dermatological Treatment that annual spending on immunomodulator medications by Medicare Part D increased 303% from $1.7 billion in 2012 to $6.9 billion in 2018. 'Immunomodulator spending is growing and may be more substantial than previously reported posing significant burden on patients and the health system,' the authors wrote.
Kong and Mostaghimi agreed, writing that 'the growing significance of specialty medications will have important implications for healthcare costs and patient affordability.'
Kong reported receiving grants from the National Institute on Aging. Mostaghimi reported receiving personal fees from Hims & Hers Health, AbbVie, Sun Pharma, Digital Diagnostics, Eli Lilly, Equillium, ASLAN Pharmaceuticals, Boehringer Ingelheim, Figure 1, Indomo, Olaplex, Legacy Healthcare, Pelage, Q32 Bio, Astria Therapeutics, ACOM Health, Bioniz, Concert, and Digital Diagnostics; equity from ACOM Health, Figure 1, and Hims & Hers Health; licensing or royalties from Concert and Pfizer; and research funding from Aclaris, Concert, Eli Lilly, and Incyte outside the submitted work.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
29 minutes ago
- Bloomberg
Roche May Sell Drugs Directly to US Patients to Bypass Middlemen
Roche Holding AG is weighing direct-to-patient drug sales in the US, bypassing the middleman for its pricey medicines for multiple sclerosis, eye disease and cancer. The Swiss drugmaker has discussed direct-to-patient sales with the US government, Chief Executive Officer Thomas Schinecker said on Thursday as the company reported quarterly earnings. The move would bring down costs 'quite quickly,' he said.
Yahoo
40 minutes ago
- Yahoo
Nurse, 26, Lost 270 Pounds After Making These 3 Lifestyle Changes
When his doctor prescribed the first blood pressure medication, Kevin Goode knew his weight probably contributed to it. He was 465 pounds, but he thought his high blood pressure wasn't 'too serious.' Still, it remained high, and his doctor prescribed him a second drug to try to lower it. Soon after, he learned he had sleep apnea and his A1C was 'shooting upward.' If it didn't lower, Goode would need to add insulin to his growing list of prescriptions. Then his doctor gave him a warning. 'My doctor told me that I wouldn't live past 40 with this trend,' Goode, 28, a nurse at Riley Hospital for Children in Indianapolis, tells 'That's the moment that everything changed.' At the time, he was 26 and visited a bariatric surgeon for a consultation. The doctor advised Goode that he needed to lose weight before he qualified for surgery. He immediately headed to the gym and sat on a bench to lift some dumbbells. Soon, he started eating a moderate-fat, low-carbohydrate and high-protein diet. '(The doctor) wanted me to lose 20 pounds because that would show that I was dedicated enough for surgery,' Goode explains. 'I ended up losing 80 pounds.' In December 2023, he underwent surgery. As he recovered for six weeks, he was anxious to get back to his exercise routine. 'I was very much like, 'How soon can I get back to the gym?'' he says. 'I was sitting around doing nothing, and I'm not liking it.' Six weeks later, he was cleared to return to his regular exercise routine. Over time, he shed more weight, reaching 176 pounds. 'My goal from the beginning of this whole journey back in February of 2023 was, bluntly, to win back my life. It was never about the weight, never about the bodybuilding, never about looking good,' he says. 'It was very much about (how) I was told that I wouldn't live past 40, and that didn't sit right with me, and I wanted to get rid of all the diagnoses.' This year, Goode took his love of weight training to the next level and is working toward becoming a certified personal trainer. One of the trainers in the gym approached Goode and suggested he consider participating in a bodybuilding competition. 'He was like 'Have you ever thought about doing a show?' and I was like, 'No, I just love it here and I come for the health aspect,'' Goode recalls. 'That's when I looked into the transformation competition.' A transformation competition generally focuses on people who have lost weight. Goode will compete in October in Chicago. As part of his preparation, he has focused more on lifting and less on cardiovascular exercise. 'Instead of doing 45 minutes of strength training and 30 of cardio, it's more like an hour strength training and maybe 15 minutes cardio,' he says. This caused him to gain some weight, and he's now at 210 pounds, but it's 'more muscle.' His diet has changed, too, and he focuses on counting macronutrients. He still eats a lot of protein, but with lower-fat foods and now incorporates complex carbohydrates into his diet. Losing fat while gaining muscle has changed his outlook on calories and how important they are for energy, he says. Since losing weight and transforming his body with lifting, Goode feels he's become 'more emotionally intelligent.' 'I share a lot more about myself,' he says. 'I'm 20 times more confident than I have ever been in my life.' Ahead, Goode shares what worked for him when it came to transforming his body. 'Nutrition Is Going To Be Your Biggest Thing' Eating fewer calories than he burned, what's known as a calorie deficit, helped Goode shed the weight. 'Nutrition is going to be your biggest thing,' he says. 'The biggest advice as far as actually losing weight is just (being in) a calorie deficit.' 'Fall in Love with the Small Wins' Focusing too much on the scale can feel overwhelming. People might think they look great, but the scale shows their weight increased slightly. Instead of focusing on the numbers, Goode urges people to 'fall in love with the small wins.' Goode keeps a running list of his in his notes app. 'I don't have to pick up my foot to tie my shoe. I can just bend over,' he says. 'I always made a joke that laptops are not laptops. There's no way that is sitting on my lap. But now I'm like I got all this room.' But his 'biggest non-scale victory' has been the difference he's noticed at work. 'Being able to move around (the hospital) room a lot easier, being able to play with the kids without getting out of breath,' he says. 'I enjoy it so much more now because I'm not getting (to) the end of the 12-hour shifts completely, like, dead.' Find Support While Goode taught himself how to work out, he hasn't been entirely alone in his process. 'I had the community support from the gym. My mom has been a huge supporter. All the nurses at work, they've been fantastic,' he says. 'I can't go without mentioning my amazing girlfriend. She's just been super supportive.' This article was originally published on


Medscape
an hour ago
- Medscape
Loneliness May Drive Depression, Poor Physical Health
TOPLINE: Frequent loneliness was associated with a higher probability of depression and an increased number of poor mental and physical health days per month than never feeling lonely in a new survey-based study. Additionally, significant disparities were observed across sex, race/ethnicity, and age groups. METHODOLOGY: Investigators assessed data for more than 47,000 US adults (62% women; 73% White individuals) obtained from the Behavioral Risk Factor Surveillance System between 2016 and 2023. They analyzed the potential association between loneliness and key health outcomes, including a diagnosis of depression and the self-reported number of days in the past month with poor mental or physical health. Participants self-reported the frequency of feeling lonely, which was categorized as always, usually, sometimes, rarely, and never. TAKEAWAY: Participants who reported always, usually, sometimes, and rarely feeling lonely had a significantly higher probability of depression (50%, 48%, 31%, and 16%, respectively; P < .001 for all) than those who reported never feeling lonely (10%). Those who reported always feeling lonely had 10.9 more poor mental health days and 5 more poor physical health days in a month on average than those who were never lonely (P < .001 for all). Women had a higher probability of depression than men across all loneliness levels (P < .001). There was also a significantly greater number of poor mental health days in women vs men who felt lonely sometimes (mean difference, 0.8 days; P = .002) and rarely (mean difference, 0.7 days; P = .003). Black and Hispanic individuals reporting loneliness had significantly lower probabilities of depression than their White peers (P < .05 for both). Among participants who felt always lonely, Black individuals reported fewer poor mental health days (mean difference, -3.8 days; P = .005) and fewer poor physical health days (mean difference, -3.6 days; P = .01) in a month than White individuals. Middle-aged (45-64 years) and older adults (> 64 years) with loneliness reported a greater number of poor physical health days in a month than younger adults (18-44 years) across all loneliness categories (P < .001 for all). However, older adults had a significantly lower risk for depression than younger adults across most loneliness levels. IN PRACTICE: 'Addressing loneliness may not only improve individual well-being but also reduce societal healthcare burdens,' the investigators wrote. 'The findings of this study carry urgent policy and practice implications. Given the pervasiveness and potency of loneliness, it should be prioritized alongside traditional risk factors in public health planning,' they added. SOURCE: The study was led by Oluwasegun Akinyemi, MD, PhD, Howard University College of Medicine, Washington, DC. It was published online on July 9 in PLOS One. LIMITATIONS: Key limitations included the study's cross-sectional design, residual confounding by unmeasured factors, and its reliance on self-reported measures. Additionally, telephone-based survey methods may have underrepresented the most socially isolated individuals. DISCLOSURES: The study was funded in part by the National Institute on Minority Health and Health Disparities. The investigators reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.